{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:15:15Z","timestamp":1786403715897,"version":"build-2736575974"},"reference-count":56,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response rate estimates at week 12 are 62.9% (95% CrI 42.5\u201379.9%) for abrocitinib 200 mg and 43.0% (95% CrI 24.8\u201364.0%) for abrocitinib 100 mg. Abrocitinib has shown a faster effect than dupilumab as regards early alleviation of itch. Because of the incomplete target selectivity of JAK inhibitors, when abrocitinib treatment is considered, laboratory screening is necessary, latent tuberculosis must be screened for, active infections are a contraindication, and special caution must be exerted in treating elderly patients and those predisposed to thromboembolic events. Even though recent meta-analyses of clinical trials have not shown that atopic dermatitis, or its treatment with JAK inhibitors or dupilumab, modify the risk of deep venous thrombosis or pulmonary embolism, long-term follow-up studies will better define the safety profile of abrocitinib.<\/jats:p>","DOI":"10.3390\/pharmaceutics15020385","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T03:26:41Z","timestamp":1674444401000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-5521","authenticated-orcid":false,"given":"Helena","family":"Iznardo","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain"},{"name":"Sant Pau Teaching Unit, School of Medicine, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Ro\u00e9","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain"},{"name":"Sant Pau Teaching Unit, School of Medicine, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-0300","authenticated-orcid":false,"given":"Esther","family":"Serra-Baldrich","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain"},{"name":"Sant Pau Teaching Unit, School of Medicine, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain"},{"name":"Sant Pau Teaching Unit, School of Medicine, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic Dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Deckers, I.A.G., McLean, S., Linssen, S., Mommers, M., van Schayck, C.P., and Sheikh, A. (2012). Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990-2010: A Systematic Review of Epidemiological Studies. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039803"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaci.2004.01.778","article-title":"The Natural Course of Atopic Dermatitis from Birth to Age 7 Years and the Association with Asthma","volume":"113","author":"Illi","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT Signalling in Inflammatory Skin Diseases with Small Molecule Inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shawky, A.M., Almalki, F.A., Abdalla, A.N., Abdelazeem, A.H., and Gouda, A.M. (2022). A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051001"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus Kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT Signaling Pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus Kinase Inhibitor JTE-052 Improves Skin Barrier Function through Suppressing Signal Transducer and Activator of Transcription 3 Signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tsiogka, A., Kyriazopoulou, M., Kontochristopoulos, G., Nicolaidou, E., Stratigos, A., Rigopoulos, D., and Gregoriou, S. (2022). The JAK\/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154431"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/ced.12273","article-title":"An Insight into JAK-STAT Signalling in Dermatology","volume":"39","author":"Palanivel","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14740338.2020.1728252","article-title":"Safety Considerations When Using Drugs to Treat Pruritus","volume":"19","author":"Fourzali","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic Dermatitis: An Expanding Therapeutic Pipeline for a Complex Disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-Pyrrolo[2,3-d]Pyrimidin-4-Yl)Amino]Cyclobutyl}propane-1-Sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus Kinases in Immune Cell Signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/366129a0","article-title":"The Protein Tyrosine Kinase JAK1 Complements Defects in Interferon-Alpha\/Beta and -Gamma Signal Transduction","volume":"366","author":"Briscoe","year":"1993","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13318-021-00745-6","article-title":"Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals","volume":"47","author":"Wang","year":"2022","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/jcph.1858","article-title":"Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites","volume":"61","author":"Wang","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcph.1980","article-title":"Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites","volume":"62","author":"Wang","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-021-01104-z","article-title":"Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis","volume":"61","author":"Wojciechowski","year":"2022","journal-title":"Clin. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Derm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and Safety of Abrocitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis (JADE MONO-1): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Derm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Derm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib Induction, Randomized Withdrawal, and Retreatment in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Phase 3 Trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","article-title":"Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis after Switching from Dupilumab (JADE EXTEND)","volume":"87","author":"Shi","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and Safety of Abrocitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomised, Double-Blind, Multicentre Phase 3 Trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/bcp.13612","article-title":"Evaluation of a Janus Kinase 1 Inhibitor, PF-04965842, in Healthy Subjects: A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study","volume":"84","author":"Peeva","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s13555-022-00764-4","article-title":"Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial","volume":"12","author":"Gooderham","year":"2022","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/DER.0000000000000770","article-title":"Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies","volume":"32","author":"Kim","year":"2021","journal-title":"Dermatitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/jdv.17813","article-title":"Patient-Reported Outcomes from the JADE COMPARE Randomized Phase 3 Study of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis","volume":"36","author":"Thyssen","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s13555-022-00694-1","article-title":"Rapidity of Improvement in Signs\/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study","volume":"12","author":"Alexis","year":"2022","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/jdv.17792","article-title":"Impact of Oral Abrocitinib on Signs, Symptoms and Quality of Life among Adolescents with Moderate-to-Severe Atopic Dermatitis: An Analysis of Patient-Reported Outcomes","volume":"36","author":"Cork","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","article-title":"Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Derm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdin.2021.05.004","article-title":"Economic Impact of Abrocitinib Monotherapy and Combination Therapy in Patients with Moderate-to-Severe Atopic Dermatitis: Results from JADE MONO-2 and JADE COMPARE","volume":"4","author":"Gooderham","year":"2021","journal-title":"JAAD Int."},{"key":"ref_38","first-page":"E136","article-title":"randomized, double-blind, placebo-controlled, parallel group, multi-center study to investigate the mechanism of action of abrocitinib monotherapy in adult participants with moderate-to-severe atopic dermatitis","volume":"185","author":"Bissonnette","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_39","unstructured":"Pfizer (2022, November 06). Abrocitinib Expanded Access Protocol in Adolescents and Adults with Moderate to Severe Atopic Dermatitis: NCT04564755, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564755."},{"key":"ref_40","unstructured":"Pfizer (2022, November 06). Post Marketing Surveillance (PMS) Study for Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis (AD) in Korea: NCT05391061, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05391061."},{"key":"ref_41","unstructured":"Pfizer (2022, November 06). A Prospective, Single-Arm, Multicenter, Observational Non-Interventional Study (NIS) in Germany of Patient Characteristics, Usage and Effectiveness of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis (AD): NCT05250115, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05250115."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s13555-022-00721-1","article-title":"Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-Analysis","volume":"12","author":"Silverberg","year":"2022","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","article-title":"The Safety of Systemic Janus Kinase Inhibitors in Atopic Dermatitis: A Systematic Review and Network Meta-Analysis","volume":"78","author":"Alves","year":"2022","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/imt-2021-0224","article-title":"Comparing Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis: A Plain Language Summary","volume":"14","author":"Bieber","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/1744666X.2022.2126353","article-title":"An Evaluation of Abrocitinib for Moderate-to-Severe Atopic Dermatitis","volume":"18","author":"Labib","year":"2022","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian Atopic Dermatitis Phenotype Combines Features of Atopic Dermatitis and Psoriasis with Increased TH17 Polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/1744666X.2021.1828068","article-title":"Abrocitinib for the Treatment of Atopic Dermatitis","volume":"16","author":"Crowley","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1016\/j.jaip.2022.08.042","article-title":"Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis","volume":"10","author":"Reich","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/13543784.2020.1804854","article-title":"Abrocitinib: A Potential Treatment for Moderate-to-Severe Atopic Dermatitis","volume":"29","author":"Nezamololama","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_50","first-page":"86","article-title":"Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis","volume":"57","author":"Perche","year":"2023","journal-title":"Ann. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid Arthritis and Cardiovascular Disease","volume":"166","author":"Crowson","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/annrheumdis-2022-eular.1016","article-title":"The Risk of Venous Thromboembolic Events in Patients with RA Aged \u2265 50 Years with \u2265 1 Cardiovascular Risk Factor: Results from a Phase 3b\/4 Randomized Safety Study of Tofacitinib vs. TNF Inhibitors","volume":"81","author":"Fleischmann","year":"2022","journal-title":"TNF Inhibitors. Ann. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/annrheumdis-2022-eular.1234","article-title":"Risk Factors for Major Adverse Cardiovascular Events in Patients Aged \u2265 50 Years with RA and \u2265 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b\/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors","volume":"81","author":"Buch","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_55","unstructured":"EMA (2022, November 11). EMA Recommends Measures to Minimise Risk of Serious Side Effects with Janus Kinase Inhibitors for Chronic Inflammatory Disorders. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Derm."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:13:54Z","timestamp":1760120034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/2\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pharmaceutics15020385"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15020385","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]}}}